文献速递其他结缔组织病

皮下阿巴西普联合标准治疗用于活动性特发性炎性肌病的疗效与安全性:3期随机对照试验

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2025-02-21

这项3期随机双盲安慰剂对照试验评估皮下阿巴西普(125 mg每周)联合标准治疗对难治性特发性炎性肌病的疗效与安全性,148例进入双盲期、133例进入开放期。24周时IMACS DOI改善率阿巴西普组56.0%对安慰剂组42.5%(P=0.083),差异未达统计学显著;非皮肌炎亚组阿巴西普组57.1%对安慰剂组32.3%(P=0.040)。作者认为非皮肌炎亚型可能持续获益。

要点

  • 24周IMACS DOI改善率阿巴西普组56.0%对安慰剂组42.5%(P=0.083),两组相似。
  • 非皮肌炎亚组24周IMACS DOI率阿巴西普组57.1%对安慰剂组32.3%(P=0.040)。
  • 皮肌炎亚组24周IMACS DOI率阿巴西普组55.0%对安慰剂组50.0%(P=0.679)。

核心结论

  • 24周时达到改善标准的患者比例在阿巴西普组与安慰剂组之间相似。
  • 按特发性炎性肌病亚型分析提示,皮下阿巴西普对非皮肌炎亚型患者可能有持续获益。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验,纳入难治性特发性炎性肌病患者。
  • 患者接受皮下阿巴西普125 mg每周联合标准治疗(阿巴西普组)或安慰剂联合标准治疗(安慰剂组)。
  • 24周双盲期后进入开放期,评估继续阿巴西普治疗与自24周起开始阿巴西普治疗(安慰剂转阿巴西普组)至52周的结局。
  • 双盲期148例、开放期133例患者接受治疗。

主要发现

  • 主要终点24周IMACS DOI改善率阿巴西普组56.0%对安慰剂组42.5%(P=0.083)。
  • 52周IMACS DOI改善率继续阿巴西普组69.8%对安慰剂转阿巴西普组69.0%。
  • 非皮肌炎亚组24周IMACS DOI率阿巴西普组57.1%对安慰剂组32.3%(P=0.040)。
  • 皮肌炎亚组24周IMACS DOI率阿巴西普组55.0%对安慰剂组50.0%(P=0.679)。
  • 观察到的安全性特征在两组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. METHODS: In this randomized, double-blind, placebo-controlled phase III trial, patients with treatment-refractory IIM received SC abatacept (at 125 mg weekly) with SOC (abatacept group) or a placebo with SOC (placebo group). A 24-week double-blind period was followed by an open-label period to assess outcomes from continued therapy with abatacept and initiation with abatacept (placebo-to-abatacept switch group) from 24 to 52 weeks. The primary end point was International Myositis Assessment and Clinical Studies definition of improvement (IMACS DOI) at week 24. Secondary efficacy and safety end points were assessed. RESULTS: Overall, 148 (double-blind) and 133 (open-label) patients were treated. Baseline demographics were well-balanced between treatment groups and disease subtypes. At 24 weeks, improvement per IMACS DOI was 56.0% for the abatacept group and 42.5% for the placebo group (P = 0.083); at 52 weeks, improvement was 69.8% (continued abatacept) and 69.0% (placebo-to-abatacept switch). The IMACS DOI rate at 24 weeks was greater in the nondermatomyositis (non-DM) group (abatacept: 57.1%; placebo: 32.3%; P = 0.040) than the DM group (abatacept: 55.0%; placebo: 50.0%; P = 0.679). The observed safety profile was similar in both groups. CONCLUSION: The proportion of patients who met improvement criteria after 24 weeks was similar between abatacept and placebo groups. However, analysis by IIM subtype suggested there may be a sustained benefit of SC abatacept for patients with non-DM subtypes.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Lundberg IE, Song YW, et al. Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial. Arthritis Rheumatol. 2025. PMID: 39609094. doi:10.1002/art.43066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。